If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTPG.L Regulatory News (TPG)

  • There is currently no data for TPG

Form 8 (OPD) - Science Group plc

13 Aug 2021 10:58

RNS Number : 6095I
Science Group PLC
13 August 2021
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Science Group plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Science Group plc

(d) Is the discloser the offeror or the offeree?

Offeror

(e) Date position held:

The latest practicable date prior to the disclosure

12 August 2021

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

Yes, TP Group plc

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

1p Ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

0

Nil

0

(2) Cash-settled derivatives:

 

Nil

0

Nil

0

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

0

Nil

0

 

TOTAL:

Nil

0

Nil

0

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

a) Ordinary Shares of 1 pence each held by directors of Science Group plc:

 

Director

Role

Science Group Ordinary Shares

% of Science Group issued share capital

Martyn Ratcliffe

Chairman & CEO

11,412,080

27.67%

Daniel Edwards

Group Managing Director

109,000

0.26%

Peter Bertram

Independent Non-Executive Director

5,000

0.01%

 

b) Science Group plc 2021 Performance Share Plan ('PSP') granted to directors of Science Group plc:

 

Director

Maximum number of ordinary shares awarded

Date of grant

Exercise price

Exercise period

Jon Brett

10,000

7 October 2020

1 pence

7 October 2023 - 7 October 2030

Daniel Edwards

250,000

14 May 2018

1 pence

14 May 2023 - 14 May 2028

Daniel Edwards

125,000

1 October 2019

1 pence

1 October 2022 - 1 October 2029

Daniel Edwards

40,000

7 October 2020

1 pence

7 October 2023 - 7 October 2030

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

13 August 2021

Contact name:

Sarah Cole

 

Group Legal Counsel & Company Secretary

 

Telephone number:

01223 875 200

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEEEANPDFLEFEEA
Date   Source Headline
21st Nov 20228:51 amRNSForm 8.5 (EPT/NON-RI)
21st Nov 20227:00 amRNSPublication of Scheme Document
17th Nov 20229:16 amRNSForm 8.5 (EPT/NON-RI)
16th Nov 20229:03 amRNSForm 8.5 (EPT/NON-RI) - TP Group PLC
16th Nov 20228:33 amRNSForm 8.3 - TP Group PLC
14th Nov 20228:55 amRNSForm 8.5 (EPT/NON-RI)
14th Nov 20228:32 amRNSForm 8.3 - TP Group PLC
11th Nov 20228:18 amRNSForm 8.3 - TP Group PLC
10th Nov 20227:00 amRNSForm 8 (OPD) (TP Group plc)
7th Nov 20227:00 amRNSForm 8 (DD) - TP Group plc
4th Nov 202211:31 amRNSForm 8.5 (EPT/NON-RI) - TP Group PLC
4th Nov 20227:00 amRNSForm 8 (DD) - TP Group plc
3rd Nov 202210:23 amRNSForm 8.5 (EPT/NON-RI) - TP Group PLC
3rd Nov 20227:00 amRNSForm 8 (DD) - TP Group plc
2nd Nov 202211:00 amRNSForm 8.5 (EPT/NON-RI)
2nd Nov 202210:44 amRNSForm 8 (DD) - TP Group plc
2nd Nov 20227:00 amRNSForm 8 (DD) - TP Group plc
1st Nov 20224:38 pmRNSForm 8.3 - TP Group Plc
1st Nov 202210:33 amRNSRule 2.10 - M&G Letter of Intent
1st Nov 20229:25 amRNSForm 8.5 (EPT/NON-RI)
1st Nov 20227:00 amRNSForm 8 (DD) - TP Group plc
31st Oct 20225:22 pmRNSForm 8 (OPD) - TP Group plc
31st Oct 20227:00 amRNSRecommended Cash Aquisition of TP Group plc
31st Oct 20227:00 amRNSBusiness Update
26th Oct 20227:00 amRNSResignation of Auditor
27th Sep 20229:23 amRNSResult of General Meeting
21st Sep 20227:00 amRNSHalf-year Report
2nd Sep 20227:00 amRNSPublication of Accounts
15th Aug 20227:00 amRNSAudited results for year ended 31 December 2021
12th Jul 20223:43 pmRNSCompletion of Disposal
28th Jun 20221:07 pmRNS2021 Financial Update
28th Jun 202210:43 amRNSResult of Annual General Meeting
21st Jun 202211:05 amRNSSecond Price Monitoring Extn
21st Jun 202211:00 amRNSPrice Monitoring Extension
20th Jun 20222:48 pmRNSExtension to Publication of Results
1st Jun 20221:27 pmRNSNotice of AGM and Accounts Update
26th May 20224:50 pmRNSSale of Sapienza Consulting Ltd.
1st Apr 20227:00 amRNSDisposal
31st Mar 20227:00 amRNSDirectorate Change
11th Feb 20227:00 amRNSBusiness Update
16th Dec 202110:30 amRNSCredit Facility to TP Group
16th Dec 202110:26 amRNSBusiness Update
1st Nov 20217:00 amRNSBusiness and Board Update
29th Oct 20215:00 pmRNSWithdrawal of GM Requisition - Replacement
29th Oct 20211:20 pmRNSWithdrawal of GM Requisition
29th Oct 202111:21 amRNSDirectorate Change
26th Oct 20211:15 pmRNSResponse re. Science Group Announcement
26th Oct 20217:00 amRNSRequisition of General Meeting of TP Group plc
14th Oct 20217:00 amRNSDirectorate Changes
11th Oct 20217:00 amRNSTrading and Business Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.